
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc has significantly increased the probability of approval for its RP1 + Opdivo treatment in anti-PD1 failed melanoma patients to 85%, reflecting strong confidence in its clinical efficacy. The favorable safety profile of RP1 + Opdivo, indicated by a low 12.8% incidence of Grade 3 or higher treatment-related adverse events, supports its potential market acceptance. The positive IGNYTE trial results further bolster the company's outlook, suggesting robust performance compared to existing therapies in a challenging treatment landscape.
Bears say
Replimune Group Inc faces multiple critical challenges that negatively impact its stock outlook, primarily centered on the efficacy and safety data of its leading candidate, RP1, which is under scrutiny following a negative FDA assessment. The FDA's complete response letter (CRL) highlighted significant concerns regarding the adequacy of the IGNYTE trial, including issues with trial control, population heterogeneity, and insufficient evidence for proposed survival benefits, casting doubt on the regulatory approval and market potential of RP1. Furthermore, the company may confront medium- to long-term dilution risks, emphasizing existing uncertainties surrounding future funding and the viability of its early-stage oncolytic virus pipeline.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares